Abstract
Summary: Background: The efficacy and safety of interferon‐based therapy in renal transplant recipients with hepatitis C remains unclear, although a number of small clinical trials have been published addressing this issue.Aim: To evaluate efficacy and safety of antiviral therapy with interferon (interferon alone or interferon plus ribavirin) in renal transplant patients with hepatitis C by performing a systematic review of the literature with a meta‐analysis of clinical trials.Methods: The primary outcomes were sustained virological response (as a measure of efficacy) and/or drop‐out rate (as a measure of tolerability). We used the random‐effects model of DerSimonian and Laird, with heterogeneity and sensitivity analysis.Results: We identified 12 clinical trials (102 unique patients); there was one controlled study. The summary estimate for sustained virological response and drop‐out rate was 18.0% (95% CI 7.0–29.0%) and 35.0% (95% CI 20–50%), respectively. The most frequent side‐effect requiring interruption of treatment was graft dysfunction (n = 28; 71.7%). Meta‐regression analysis showed an inverse and significant association between reference year and drop‐out logit rate (P = 0.012); an inverse link between sustained virological response logit rate and frequency of hepatitis C virus genotype 1 (P = 0.067) and cirrhosis (P = 0.08) was found, even if no statistical significance was reached. No publication bias was observed.Conclusions: Interferon‐based therapy of hepatitis C has poor tolerance and safety after renal transplant. The optimal treatment of hepatitis C after renal transplant requires additional agents or alternative therapeutic approaches.

This publication has 49 references indexed in Scilit: